FDA Brief

Warning letters Drugs

FDA warning letter to

Atlanta Supersource, Inc.

High riskIssued Jan 8, 2025Posted Jan 21, 2025Center for Drug Evaluation and Research (CDER)

Atlanta Supersource made OTC hand sanitizers on equipment shared with toxic industrial chemicals and lacked testing, FDA says.

What happened

FDA inspected the Kennesaw, Georgia drug manufacturing facility from July 15 to 19, 2024. It found hand sanitizer made on the same equipment as industrial chemicals with severe skin-burn warnings, no identity or strength testing of benzalkonium chloride (BZK) before release, no identity testing of incoming components, and inadequately monitored water. FDA also said labels with “MADE IN AN FDA REGISTERED FACILITY” and an FDA-like logo misleadingly suggest FDA approval.

What FDA found

  1. The company did not adequately clean and maintain equipment used to make drugs, and it used the same equipment for toxic industrial chemicals and OTC hand sanitizers.

    21 CFR 211.67(a)
  2. The company released hand sanitizer batches without adequate laboratory testing for the identity and strength of the active ingredient, benzalkonium chloride.

    21 CFR 211.165(a)
  3. The company did not test each incoming component shipment or lot for identity and did not confirm components met purity, strength, and quality specifications before use.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  4. The company’s water system was not adequately monitored or routinely tested to ensure water met United States Pharmacopeia purified water specifications.

  5. The hand sanitizer labels included “MADE IN AN FDA REGISTERED FACILITY” and an FDA-like acronym that misleadingly suggested FDA approval, though the products were not FDA-approved.

    FD&C Act section 502(a), 21 U.S.C. 352(a)

What FDA wants

FDA tells Atlanta Supersource to respond in writing within 15 working days describing what it has done to correct the violations and prevent recurrence. FDA also asks the company to clarify whether it will resume making drugs, notify FDA before resuming, and, if it resumes, hire a qualified CGMP consultant to audit its operations.

Who should pay attention

  • companies that buy OTC drugs from contract manufacturers
  • hand sanitizer brands and distributors
  • quality teams overseeing shared equipment and supplier testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  2. Signature Formulations LLC

    FDA warns Signature Formulations about contaminated contract-manufactured drug products and cross-contamination at its Phoenix facility.

    High risk
  3. Shoolin Pharma Chem LLP

    Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.

    High risk
  4. Dabur India Limited

    FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.

    High risk